IP Library Granted Patent US 7,612,083
Granted Patent B2
US 7,612,083 · App. 11/132,900 · Granted Nov 3, 2009

Urea substituted imidazoquinoline ethers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,612,083
App. No.
11/132,900
Granted
Nov 3, 2009
Kind
B2
Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Claims (2)

1. A method of inducing cytokine biosynthesis in an animal comprising administering a compound selected from the group consisting of N-(2-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)-N′-phenylurea and N-(2-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)-N-methyl-N′-phenylurea, or a pharmaceutically acceptable salt thereof to the animal in need thereof an amount effective for cytokine induction.

2. The method of claim 1 wherein the cytokine is IFN-α and/or TNF-α.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2007
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: COLEY PHARMACEUTICAL GROUP, INC.
Reel/Frame 019943/0483 →